Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2023-03-28 00:00:00 ET · period of report 2023-03-24 · accession 0000899243-23-009799 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-03-28 | 2023-03-24 | LGND | Reardon Andrew | See Remarks | S - Sale | $69.92 | -300 | 16.3K | -2% | -$21.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-24 | S | D | 300 | $69.92 | 16,308 | D | — | — |